RAB27A and prostate carcinoma: Notably, intravenous injection of exogenous exosomes derived from WT prostate cancer cells resulted in decreased spleen size of mice injected with Rab27a-deleted prostate cancer cells to nearly 50% (Poggio et al., 2019).